Chimeric Antibody

A recombinant or genetically engineered antibody—e.g., a mouse monoclonal—which contains polypeptides or domains from a different species—e.g., humans—often introduced to reduce the antibody’s immunogenicity
Mentioned in ?
References in periodicals archive ?
- Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
Tumor Infiltrating Lymphocytes Study, 2019: A New Frontier in Cancer Immunotherapy
The sample size is increased from 15 to 50 microliters, increasing the chances of "recovery." Other modifications include signal amplification and genetic re-engineering of the chimeric antibody itself to improve precision and performance.
Clinical progress with high-sensitivity Troponin T?
Novak-Hofer et al., "Production and characterization of a mouse human chimeric antibody directed against human neuroblastoma," International Journal of Cancer, vol.
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
Hassan et al., "Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin," Cancer Immunity, vol.
Combination Immunotherapy Approaches for Pancreatic Cancer Treatment
In their pilot study, seven dogs with oral malignant melanoma (OMM) and two dogs with undifferentiated sarcoma were treated with the chimeric antibody every two weeks.
New Cancer Antibody
However, the chimeric antibody still induced human antibody responses, which is an important consideration when repeated dosing is required for, for example, scouting studies prior to therapy.
CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches
In this report, we used the unique bioengineering technology of silkworms and established a chimeric antibody (CH-CSLEX-1) with a human IgG constant region and the original binding site of the CSLEX-1 mouse IgM monoclonal antibody.
Sandwich ELISA Using a Mouse/Human Chimeric CSLEX-1 Antibody
Unituxin (dinutuximab) is a monoclonal chimeric antibody composed of murine variable heavy and light chain regions and the human constant region for the heavy chain kappa.
Clinigen Group and United Therapeutics Initiate Managed Access Program for UNITUXIN[TM] (Dinutuximab) Injection for High Risk Neuroblastoma
[11.] Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Advantages and disadvantages of targeting the C-erbB family of receptors in cancer treatment: a review
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.
Detection of PRL-3 protein in the preoperative serum of patients with colorectal cancer
Expression of chimeric antibody in mammalian cells using dicistronic expression vector.
Expression enhancement in trastuzumab therapeutic monoclonal antibody production using genomic amplification with methotrexate
The product is a monoclonal chimeric antibody developed to treat neuroblastoma, a malignant tumor developing from nerve tissue and most common in children below five years.
Paladin Labs receives commercialisation rights to APN311 from Apeiron Biologics

Medical browser ?
Full browser ?